Reata Pharmaceuticals (RETA) PT Raised to $145 at Cantor Fitzgerald
Tweet
Share
E-mailGet Alerts RETA Hot Sheet
Price: $172.36 --0%
Rating Summary:
6 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 9 | New: 8
Rating Summary:
6 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 9 | New: 8
Join SI Premium – FREE
Cantor Fitzgerald analyst Charles Duncan raised the price target on Reata Pharmaceuticals (NASDAQ: RETA) to $145.00 (from $110.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Nebius Group (NBIS) PT Raised to $300 at Compass Point
- Brainsway (BWAY) PT Raised to $18.80 at Ladenburg Thalmann
- First Tracks Biotherapeutics (TRAX) PT Raised to $95 at Piper Sandler
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
